Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioLineRx (BLRX) stocks in Canada

Learn how to easily invest in BioLineRx stocks.

BioLineRx is a biotechnology business based in the US. BioLineRx stocks (BLRX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.29 – a decrease of 4.23% over the previous week. BioLineRx employs 38 staff and has a market cap (total outstanding stock value) of $89.2 million.

How to buy shares in BioLineRx

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BLRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

BioLineRx stock price (NASDAQ:BLRX)

Use our graph to track the performance of BLRX stocks over time.

BioLineRx shares at a glance

Information last updated 2022-01-25.
Latest market close$1.81
52-week range$1.70 - $6.34
50-day moving average $2.31
200-day moving average $2.77
Wall St. target price$14.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.93

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy BioLineRx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

BioLineRx price performance over time

Historical closes compared with the close of $1.81 from 2022-01-26

1 week (2022-01-20) -4.23%
1 month (2021-12-28) -15.42%
3 months (2021-10-28) -36.93%
6 months (2021-07-28) -44.82%
1 year (2021-01-28) -38.23%
2 years (2020-01-27) -24.58%
3 years (2019-01-25) 199.27%
5 years (2017-01-27) 69.16%

Is BioLineRx under- or over-valued?

Valuing BioLineRx stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioLineRx's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioLineRx's PEG ratio

BioLineRx's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioLineRx's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

BioLineRx financials

Gross profit TTM $0
Return on assets TTM -22.61%
Return on equity TTM -72.59%
Profit margin 0%
Book value $1.50
Market capitalisation $89.2 million

TTM: trailing 12 months

BioLineRx share dividends

We're not expecting BioLineRx to pay a dividend over the next 12 months.

Have BioLineRx's shares ever split?

BioLineRx's shares were split on a 1:15 basis on 14 July 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioLineRx shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for BioLineRx shares which in turn could have impacted BioLineRx's share price.

BioLineRx share price volatility

Over the last 12 months, BioLineRx's shares have ranged in value from as little as $1.7 up to $6.34. A popular way to gauge a stock's volatility is its "beta".

BLRX.US volatility(beta: 1.46)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioLineRx's is 1.4642. This would suggest that BioLineRx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

BioLineRx overview

BioLineRx Ltd. , a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site